Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityNo recent work listed

Mengyao Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-1662-2239; OpenAlex author ID A5103210183. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2015: 3 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 8

  1. M2-phenotype tumour-associated macrophages upregulate the expression of prognostic predictors MMP14 and INHBA in pancreatic cancer. Co-author DOI 10.1111/jcmm.17191↗
  2. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/gs-20-828↗
  3. Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner. Co-author DOI 10.1097/mpa.0000000000001386↗
  4. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Co-author DOI 10.1038/s41389-018-0102-2↗
  5. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresect… Co-author DOI 10.18632/oncotarget.21340↗
  6. FH535 inhibited metastasis and growth of pancreatic cancer cells. First author DOI 10.2147/ott.s82718↗
  7. Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine an… First author DOI 10.3892/ijo.2015.3156↗
  8. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling… First author DOI 10.3892/ol.2014.2711↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Meng Shen · 6 shared papers, 2015–2022 · strength 0.54
  2. Min Tao · 7 shared papers, 2015–2020 · strength 0.50
  3. Mengdan Xu · 4 shared papers, 2018–2022 · strength 0.45
  4. Qiaoming Zhi · 4 shared papers, 2015–2019 · strength 0.27
  5. Weiming Duan · 3 shared papers, 2015–2022 · strength 0.24
  6. Kai Chen · 3 shared papers, 2015–2019 · strength 0.20
  7. Wei Li · 3 shared papers, 2015–2018 · strength 0.18
  8. Zhan‐Wen Liang · 1 shared paper, 2022 · strength 0.15
  9. Wei Li · 1 shared paper, 2022 · strength 0.15
  10. Lian Lian · 2 shared papers, 2015–2017 · strength 0.11
  11. Daoming Li · 2 shared papers, 2015 · strength 0.09
  12. Wei Li · 1 shared paper, 2019 · strength 0.08
  13. Rui Ren · 1 shared paper, 2019 · strength 0.08
  14. Xiaojie Bian · 1 shared paper, 2017 · strength 0.06
  15. Yuan Hong Gao · 1 shared paper, 2017 · strength 0.06
  16. Wenjie Wang · 1 shared paper, 2015 · strength 0.05
  17. Wei Li · 1 shared paper, 2015 · strength 0.05
  18. Yixiang Mao · 1 shared paper, 2015 · strength 0.05
  19. Xin Xie · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.